I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer is committed to doing all we can to respond to the COVID-19 pandemic. We recognize the need for the educational upskilling and sharing of knowledge to mitigate impacts on patient care and outcomes in the National Health Service (NHS) due to COVID-19. As part of our commitment, we are releasing this Request for Proposals (RFP) to provide financial support for organizations implementing educational initiatives designed to support cancer patients during this evolving crisis.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
## II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>UK only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant Eligibility Criteria</td>
<td></td>
</tr>
<tr>
<td>• Healthcare organisations, academic organisations, patient organisations, charities and other organisations with an interest in improving outcomes for patients with cancer.</td>
<td></td>
</tr>
<tr>
<td>• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations all institutions must have a relevant role and the requesting organization must have a key role in the project.</td>
<td></td>
</tr>
</tbody>
</table>

## III. Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>3rd September 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area</td>
<td>Oncology - General</td>
</tr>
<tr>
<td>General Area of Interest for this RFP:</td>
<td>COVID-19 has resulted in large changes to cancer care in the UK, resulting in interrupted and modified care for many patients living with a diagnosis of cancer. Funds are intended to be used to for initiatives that support the educational needs of healthcare professionals (HCPs) and patients regarding the management of cancer patients during the COVID-19 pandemic. Educational programs to help HCPs meet the rapidly evolving needs of cancer patients during this challenging time will be supported. Programs should be focused on one or more of the following: 1) development of online educational content for cancer patients 2) multi-disciplinary simulation education around effective tele/video services 3) educational content on effective virtual multi-disciplinary meetings 4) topics around how to train junior doctors in oncology and haematology in a virtual world 5) education on the effective utilisation of tools designed to facilitate remote interaction between cancer patients and HCPs.</td>
</tr>
</tbody>
</table>

*It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Information on how to submit requests for support of clinical research projects can be found at [https://www.pfizer.co.uk/medical-and-educational-goods-and-services-megs](https://www.pfizer.co.uk/medical-and-educational-goods-and-services-megs).*
| Target Audience: | Oncology Haemato-Oncology Healthcare Professionals  
| | Patients and Caregivers |
| Expected Approximate Monetary Range of Grant Applications: | Expected range of grant requests under this RFP is approximately £5,000 to £50,000  
| | Individual projects requesting up to a maximum of £50,000 will be considered.  
| | Funding requests should be commensurate with the scale of the proposed initiative  
| | Approximately £150,000 is available under this RFP |
| Key Dates: | RFP release date: 3rd September 2020  
| | Grant Application due date: 6th October 2020  
| | Please note the deadline is 23:59 Greenwich Mean Time (e.g. London, GMT 0).  
| | Anticipated Grant Award Notification Date: 28th October 2020  
| | Grants will be distributed following a fully executed agreement.  
| | Anticipated Project Start and End Dates: December 2020 to December 2021. Maximum project execution time is 1 year. |
| How to Submit: | Please go to [https://www.cybergrants.com/pfizer/knowledge](https://www.cybergrants.com/pfizer/knowledge) and sign in. First-time users should click “Create your password”.  
| | In the application:  
| | - For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes  
| | Select the following Competitive Grant Program Name:  
| | - 2020 Oncology UK: Continuity in Care for Patients with Cancer During COVID-19 Pandemic  
| | - Select the following Primary Area of Interest: Oncology  
| | Requirements for submission:  
| | Complete all required sections of the online application and upload your project proposal (see Appendix) in the Full Proposal Submission field.  
| | If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.  
<p>| <strong>IMPORTANT:</strong> Be advised applications submitted after the due date will not be reviewed by the committee. |</p>
<table>
<thead>
<tr>
<th>Questions:</th>
<th>If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop (<a href="mailto:Jacqueline.Waldrop@Pfizer.com">Jacqueline.Waldrop@Pfizer.com</a>), with the subject line “Continuity in Care for Patients with Cancer During COVID-19 Pandemic”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review and Approval Process</td>
<td>Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.</td>
</tr>
<tr>
<td>Mechanism by which Applicants will be Notified:</td>
<td>All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification during the review period.</td>
</tr>
</tbody>
</table>
Appendix A  
Project Description

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

| Goals and Objectives                                                                 | • Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organisation(s).
|                                                                                     | • List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.
| Needs Assessment for the Project                                                   | • Include a description of your organization’s needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
| Target Audience                                                                   | • Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
| Project Design and Methods                                                         | • Describe the planned project, the educational approach, and the way the planned methods address the established need.
| Innovation                                                                        | • Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.
| Evaluation and Outcomes                                                            | • In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.
### Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

### Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

### Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

### Organization Detail

- Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.

### Budget Narrative

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.

- While estimating your budget please keep the following items in mind:
  - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
  - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.